These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 33843899)

  • 1. The importance of exposing patients with metastatic colorectal cancer to all treatment options.
    Loupakis F
    Clin Adv Hematol Oncol; 2021 Jan; 19 Suppl 3(1):3-5. PubMed ID: 33843899
    [No Abstract]   [Full Text] [Related]  

  • 2. Metastatic colorectal cancer: strategies for third-line treatment.
    Marshall JL
    Clin Adv Hematol Oncol; 2021 Jan; 19 Suppl 3(1):7-15. PubMed ID: 33843901
    [No Abstract]   [Full Text] [Related]  

  • 3. Identifying disease progression in patients with metastatic colorectal cancer: when to initiate third-line therapy.
    Bekaii-Saab TS
    Clin Adv Hematol Oncol; 2020 Jan; 18 Suppl 2(1):2-7. PubMed ID: 33843904
    [No Abstract]   [Full Text] [Related]  

  • 4. First-line treatment options for patients with metastatic colorectal cancer.
    Schilsky RL
    Nat Clin Pract Oncol; 2004 Dec; 1(2):70-1. PubMed ID: 16264820
    [No Abstract]   [Full Text] [Related]  

  • 5. Options for patients with metastatic colorectal cancer who progress after second-line therapy.
    Marshall JL
    Clin Adv Hematol Oncol; 2019 Mar; 17 Suppl 7(3):2-4. PubMed ID: 31730589
    [No Abstract]   [Full Text] [Related]  

  • 6. The importance of keeping patients with metastatic colorectal cancer on treatment through the management of adverse events.
    Grothey A
    Clin Adv Hematol Oncol; 2020 Oct; 18 Suppl 16(10):15-19. PubMed ID: 33843851
    [No Abstract]   [Full Text] [Related]  

  • 7. New possibilities in chemotherapy for colorectal cancer.
    Bekradda M; Cvitkovic E
    Ann Oncol; 1999; 10 Suppl 6():105-11. PubMed ID: 10676561
    [No Abstract]   [Full Text] [Related]  

  • 8. The handling of metastatic colorectal cancer.
    Fornarini G; Guglielmi A; Sobrero A
    Ann Oncol; 2005; 16 Suppl 2():ii141-3. PubMed ID: 15958445
    [No Abstract]   [Full Text] [Related]  

  • 9. Recent advances in the treatment of metastatic colorectal cancer in Taiwan.
    Lin YL; Yeh KH; Cheng AL
    J Formos Med Assoc; 2011 Jan; 110(1):1-3. PubMed ID: 21316006
    [No Abstract]   [Full Text] [Related]  

  • 10. [First-line chemotherapy for unresectable and metastatic colorectal cancer].
    Satoh T
    Gan To Kagaku Ryoho; 2014 Nov; 41(11):1372-5. PubMed ID: 25577805
    [No Abstract]   [Full Text] [Related]  

  • 11. [A review of FOLFOXIRI chemotherapy for the 1st line treatment of metastatic colorectal cancer].
    Kawakami H; Satoh T; Nakagawa K
    Nihon Rinsho; 2011 Apr; 69 Suppl 3():439-45. PubMed ID: 22214001
    [No Abstract]   [Full Text] [Related]  

  • 12. Chemotherapy and immunotherapy in metastatic colorectal cancer.
    Frati L; Codacci-Pisanelli G
    N Engl J Med; 2009 May; 360(20):2134-5; author reply 2135-6. PubMed ID: 19445031
    [No Abstract]   [Full Text] [Related]  

  • 13. FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
    Cremolini C; Loupakis F; Falcone A
    N Engl J Med; 2015 Jan; 372(3):291-2. PubMed ID: 25587960
    [No Abstract]   [Full Text] [Related]  

  • 14. FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
    Matsuoka A; Maeda O; Ando Y
    N Engl J Med; 2015 Jan; 372(3):291. PubMed ID: 25587962
    [No Abstract]   [Full Text] [Related]  

  • 15. FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
    Haines IE
    N Engl J Med; 2015 Jan; 372(3):290-1. PubMed ID: 25587961
    [No Abstract]   [Full Text] [Related]  

  • 16. FOLFIRI+bevacizumab induction chemotherapy followed by bevacizumab or observation in metastatic colorectal cancer, a phase III trial (PRODIGE 9--FFCD 0802).
    Aparicio T; Linot B; Le Malicot K; Bouché O; Boige V; François E; Ghiringhelli F; Legoux JL; Ben Abdelghani M; Phelip JM; Faroux R; Dahan L; Taieb J; Bedenne L
    Dig Liver Dis; 2015 Apr; 47(4):271-2. PubMed ID: 25677925
    [No Abstract]   [Full Text] [Related]  

  • 17. Refining the use and sequencing of third-line therapy in patients with metastatic colorectal cancer.
    Grothey A
    Clin Adv Hematol Oncol; 2020 Jan; 18 Suppl 2(1):7-14. PubMed ID: 33843905
    [No Abstract]   [Full Text] [Related]  

  • 18. Maintenance therapy in metastatic colorectal cancer.
    Marshall JL
    Clin Adv Hematol Oncol; 2014 Jun; 12(6):388-90. PubMed ID: 25003569
    [No Abstract]   [Full Text] [Related]  

  • 19. Regorafenib with a fluoropyrimidine for metastatic colorectal cancer after progression on multiple 5-FU-containing combination therapies and regorafenib monotherapy.
    Marks EI; Tan C; Zhang J; Zhou L; Yang Z; Scicchitano A; El-Deiry WS
    Cancer Biol Ther; 2015; 16(12):1710-9. PubMed ID: 26561209
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gastrointestinal cancer: FOLFOXIRI-improving outcomes of metastatic colorectal cancer.
    Errico A
    Nat Rev Clin Oncol; 2014 Dec; 11(12):684. PubMed ID: 25384949
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.